Phase 2Completed

A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients

A Phase IIa, Open-label, Randomized Trial in Treatment-naive HIV-1-infected Subjects to Determine the Antiviral Activity of 14 Days of Monotherapy With 4 Different Dose Regimens of TMC310911 Coadministered With Ritonavir

Sponsor
Tibotec Pharmaceuticals, Ireland (Industry)
Enrollment
33 enrolled
Conditions
Human Immunodeficiency Virus Type 1
Interventions
TMC310911 75 mg twice daily; TMC310911 150 mg twice daily; TMC310911 300 mg twice daily; TMC310911 300 mg once daily; Ritonavir 100 mg twice daily; Ritonavir 100 mg once daily
Ages
adults
Registry
NCT00838162, EUCTR2008-008190-58

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to evaluate the antiviral activity as measured by the change in viral load from baseline in the 14 days following initiation of treatment with 4 different dose regimens of TMC310911 co-administered with ritonavir.

Primary outcomes

  • Mean Changes From Baseline in Plasma log10 Human Immunodeficiency Virus Type 1 Ribonucleic Acid (HIV-1 RNA)

History

  1. Last registry update

  2. Results first posted

  3. Study completion

  4. Primary completion

  5. Started

  6. Registered